References
Original articles
Facon, T. et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2400712 (2024)
Leleu, X. et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat. Med. https://doi.org/10.1038/s41591-024-03050-2 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM. Nat Rev Clin Oncol 21, 565 (2024). https://doi.org/10.1038/s41571-024-00918-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-024-00918-7
- Springer Nature Limited